Home / Business and Economy / Biosimilar Bill Speeds Drug Access, Cuts Costs
Biosimilar Bill Speeds Drug Access, Cuts Costs
31 Jul
Summary
- Legislation aims to expedite biosimilar drug approvals.
- Estimated savings of $150 million for manufacturers.
- Potential to bring drugs to patients two to four years sooner.
A significant legislative advancement occurred last week as Senator Rand Paul's proposed Expedited Access to Biosimilars Act was unanimously approved by the Senate Health, Education, Labor, and Pensions (HELP) Committee. This bill seeks to streamline the approval pathway for biosimilar medications.
Biosimilars are highly similar to already-approved biologic drugs, which are produced using living systems. These include treatments for conditions like allergies, arthritis, cancer, diabetes, and macular degeneration.
The proposed act would codify earlier Food and Drug Administration (FDA) guidance, reducing the burden on competing pharmaceutical companies. Currently, manufacturers often face costly, full clinical trials for biosimilars.
Under the new legislation, the FDA would approve biosimilars based on analytical tests showing similar patient metabolism to brand-name drugs. This change is expected to eliminate unnecessary trial expenses, as no biosimilar passing such tests has previously failed FDA approval.
Estimates suggest these reforms could save biosimilar manufacturers up to $150 million in development costs. Furthermore, the bill could accelerate patient access by two to four years, while also likely encouraging lower prices for both biosimilar and brand-name drugs.
